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Neurobiology of Disease
Anti-ApoE Antibody Given after Plaque Onset Decreases A
Accumulation and Improves Brain Function in a Mouse
Model of A Amyloidosis
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Katheryn B. Lefton,1,2,3 Tony J. Zhang,1,2,3 Joshua T. Dearborn,5 Jungsu Kim,8 Joseph P. Culver,4 Rebecca Betensky,9
David F. Wozniak,2,5,7 Bradley T. Hyman,6 and David M. Holtzman1,2,3
1Department of Neurology, 2Hope Center for Neurological Disorders, 3Charles F. and Joanne Knight Alzheimer’s Disease Research Center, 4Department of
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Apolipoprotein E (apoE) is the strongest known genetic risk factor for late onset Alzheimer’s disease (AD). It influences amyloid- (A)
clearance and aggregation, which likely contributes in large part to its role in AD pathogenesis. We recently found that HJ6.3, a mono-
clonal antibody against apoE, significantly reduced A plaque load when given to APPswe/PS1E9 (APP/PS1) mice starting before the
onset of plaque deposition. To determine whether the anti-apoE antibody HJ6.3 affects A plaques, neuronal network function, and
behavior in APP/PS1mice after plaque onset, we administered HJ6.3 (10mg/kg/week) or PBS intraperitoneally to 7-month-old APP/PS1
mice for 21weeks. HJ6.3mildly improved spatial learning performance in thewatermaze, restored resting-state functional connectivity,
andmodestly reduced brain A plaque load. There was no effect of HJ6.3 on total plasma cholesterol or cerebral amyloid angiopathy. To
investigate the underlying mechanisms of anti-apoE immunotherapy, HJ6.3 was applied to the brain cortical surface and amyloid
deposition was followed over 2 weeks using in vivo imaging. Acute exposure to HJ6.3 affected the course of amyloid deposition in that it
prevented the formationofnewamyloiddeposits, limited their growth, andwasassociatedwithoccasional clearanceofplaques, aprocess
likely associated with direct binding to amyloid aggregates. Topical application of HJ6.3 for only 14 d also decreased the density of
amyloid plaques assessed postmortem. Collectively, these studies suggest that anti-apoE antibodies have therapeutic potential when
given before or after the onset of A pathology.
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Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder char-
acterized by the impairment of memory and other cognitive
functions, as well as the presence of extracellular amyloid plaques
and intracellular neurofibrillary tangles (Holtzman et al., 2011).
There is substantial evidence indicating that amyloid- (A)
plays a key role in the development of AD (Hardy and Selkoe,
2002; Lemere andMasliah, 2010). Previous therapeutic strategies
for AD, including A immunotherapy (Schenk et al., 1999; Bard
et al., 2000), have focused on decreasing A accumulation or
removing existing A aggregates by enhancing A clearance.
Certain types of active and passive immunization have resulted in
significant side effects such as brain edema and hemorrhages
(Brody and Holtzman, 2008). Given that A metabolism is reg-
ulated by A-binding proteins, immunization approaches tar-
geted against proteins that regulate A metabolism could also
provide another treatment avenue, potentially with fewer side
effects.
The 4 allele of apolipoprotein E (apoE) has been established
as the strongest genetic risk factor for late-onset AD (Corder et
al., 1993; Strittmatter et al., 1993a; Strittmatter et al., 1993b;
Corder et al., 1994; Belinson and Michaelson, 2009). There is
compelling evidence showing that apoE affects A accumulation
by modulating both A aggregation (Ma et al., 1994; Wisniewski
et al., 1994) and clearance (Sadowski et al., 2006; Deane et al.,
2008; Jiang et al., 2008; Castellano et al., 2011) and it also colo-
calizes with A plaques (Namba et al., 1991). Recently, we found
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that passive immunization of APPswe/PS1E9 (APP/PS1) mice
before A plaque onset resulted in a strong decrease of A
plaques and insoluble A40 and A42 levels (Kim et al., 2012).
However, it is unknown whether passive apoE immunotherapy
that begins after the presence of amyloid deposition in the brain
would have similar effects. In addition, the potentialmechanisms
of the anti-amyloid effects and whether apoE immunotherapy
benefits brain function have not been explored.
Here, we treated 7-month-old APP/PS1 mice that had preex-
isting A plaques with the anti-apoEmonoclonal antibodyHJ6.3
for 21 weeks. We assessed changes in spatial learning and mem-
ory, intrinsic functional connectivity, and A pathology associ-
ated with this treatment. In addition, we examined possible side
effects including hypercholesterolemia, cerebral amyloid angiop-
athy (CAA), and CAA-associated microhemorrhage. With the
aim of understanding the mechanisms of anti-apoE immuno-
therapy dynamically, we performed in vivo 2-photon imaging
over 2 weeks after acute HJ6.3 exposure to the cortical surface.
The results suggest that HJ6.3 prevents new plaque formation,
inhibits A plaque growth, favors the clearance of amyloid aggre-
gates, and improves brain function.
Materials andMethods
Chronic antibody administration and pathology assessment. Seven-
month-old female APPswe/PS1E9 (APP/PS1) mice on a B6C3 back-
ground (Jankowsky et al., 2004) were injected intraperitoneally with a
weekly dose of 10 mg/kg body weight of anti-apoE mouse monoclonal
antibody HJ6.3 (Kim et al., 2012) or PBS for 21 weeks. HJ6.3 is an IgG2b
antibody. During the last 4 weeks of treatment, behavioral performance
of the mice was tested. Two days after the final injection, functional
connectivity optical intrinsic signal imaging (fcOIS) was recorded. Im-
mediately after fcOIS, blood was collected via cardiac puncture and then
the mice were perfused with ice-cold PBS containing 0.3% heparin. One
hemibrain was fixed in 4% paraformaldehyde for histological analysis of
amyloid plaque load, CAA, CAA-associated microhemorrhages, apoE,
and microglial immunoreactivity. The other hemibrain was dissected
and flash-frozen on dry ice for biochemical assays for A and apoE. Data
in all the figures are expressed asmean SEMunless otherwise specified.
All experimental protocols were approved by the Animal Studies Com-
mittee at Washington University, Massachusetts General Hospital Sub-
committee for Research, and the Animal Care and Use Committee at
Harvard Medical School.
Immunohistochemistry. Serial coronal sections at 50 m thickness
were collected from the rostral to the caudal end of each brain hemi-
sphere using a freezing sliding microtome (Leica). A plaques were im-
munostained using biotinylated anti-A1–13 monoclonal antibody
HJ3.4B (Bero et al., 2012). ApoE was immunostained using anti-apoE
HJ6.8B (generated in-house), which recognizes a different epitope of
apoE than HJ6.3. Activated microglia were immunostained using rat-
anti CD45 (AbD Serotec), followed by biotinylated goat anti-rat IgG
secondary antibody (Life Technologies). Quantitative analysis of immu-
nopositive staining was performed as described previously (Bero et al.,
2012). Briefly, images of immunostained sections were exported with
NDP viewer (Hamamatsu Photonics), converted to 8-bit grayscale using
ACDSee Pro 2 software (ACDSystems), thresholded to highlight positive
staining, and analyzed using ImageJ software. Three sections per mouse
(bregma,1.4 mm caudal to bregma,2.0 mm caudal to bregma) were
quantified (hippocampus and overlying cortex) and the averagewas used
to represent each mouse. For CAA quantification, the values from indi-
vidual mice were normalized according to the average value of control
group. Two-tailed Student’s t test was used to analyze the data.
ELISA. Brain cortices were sequentially homogenized with cold PBS,
1% Triton-X 100, and 5 M guanidine buffer in the presence of 1 pro-
tease inhibitor mixture (Roche). The levels of Ax-40 and apoE were
measured by sandwich ELISA. For Ax-40 ELISA, anti-A35–40 HJ2 was
used as a capture antibody and anti-A13–18 HJ5.1-biotin (Bero et al.,
2011) was used as the detecting antibody. For apoE, HJ6.4 (Kim et al.,
2012) was used as the capture antibody and HJ6.1-biotin (Kim et al.,
2012) as the detecting antibody. Pooled C57BL/6J plasma was used as a
quantification standard for murine apoE (Kim et al., 2012). Two-tailed
Student’s t test was used to analyze the data.
Total plasma cholesterol. Total plasma cholesterol was assessed using a
commercial kit (catalog #439-17501; Wako Chemicals) following the
manufacturer’s instructions. Two-tailed Student’s t test was used to an-
alyze the data.
Staining and quantitative analysis of CAA-associated microhemorrhage.
Prussian blue staining was performed to identify microhemorrhages
(Fryer et al., 2003). Briefly, 15–18 equally spaced 50msections, 300m
apart, were assessed from eachmouse. Sections weremounted on Super-
frost slides and dried overnight. Sections were rehydrated in PBS, fol-
lowed by permeablizing in PBS–Triton X-100 (0.25%) for 10 min. After
being washed twice with 0.9% NaCl for 2 min/each, sections were incu-
bated in 2%HCl containing 2%potassium ferrocyanide for 20min. After
washing with PBS, the sections were costained with 0.025% Thioflavin S
(ThioS) to confirm that any putative microhemorhages were associated
with CAA. The blue puncta stained by Prussian blue were counted with a
light microscope. ThioS staining was visualized under the 488 nm fluo-
rescent emission range. Two-tailed Student’s t test was used to analyze
the data.
One hour locomotor activity and sensorimotor battery. Locomotor ac-
tivity was evaluated in HJ6.3-treated (n 19) and PBS-treated (n 18)
mice over a 1 h period using transparent (47.6  25.4  20.6 cm high)
polystyrene enclosures and computerized photobeam instrumenta-
tion, as described previously (Wozniak et al., 2004). Variables per-
taining to general ambulatory activity (total ambulations) and
exploratory behaviors (vertical rearings) were analyzed. All mice were
also evaluated on a battery of sensorimotor tests to assess balance
(ledge and platform), strength (inverted screen), coordination (pole
and inclined screens), and initiation of movement (walking initia-
tion) using previously published procedures (Wang et al., 2002;
Wozniak et al., 2004). One-way ANOVAmodels were used to analyze
differences between groups.
Morris water maze navigation. Spatial learning and memory capabili-
ties of theAPP/PS1micewere assessed in theMorris watermaze (MWM)
after 4–5months of treatment with HJ6.3 or PBS at 11–12months of age
using a computerized tracking system (ANY-maze; Stoelting) that in-
volved procedures similar to those previously described (Wozniak et al.,
2004). The protocol included conducting cued (visible platform), place
(submerged and hidden platform), and probe (platform removed) trials
in a round pool (118 cm inner diameter) of opaquewater.Mice were first
trained on the cued condition (11 months of age) to determine whether
nonassociative factors were likely to affect acquisition performance dur-
ing subsequent place trials. Unlike our typical water maze procedures, in
which mice experience 2 consecutive days of cued trials, the mice in the
present study received 4 trials per day (60 s maximum) for 5 consecutive
days in an effort to provide additional training to compensate for poten-
tially poor swimming abilities in the APP/PS1 mice. The cued trials in-
volved moving the platform to a different location for each trial using a
30 min intertrial interval (ITI) in the presence of very few distal spatial
cues to limit spatial learning. Three days after completing the cued trials,
the mice were trained on the “place” condition to learn the location of a
submerged platform. The place trials were conducted in the presence of
several salient distal cues positioned around the room to facilitate asso-
ciation of the spatial cues with the submerged platform, which remained
in the same location for all trials. During the place trials, the mice re-
ceived 2 blocks of 2 consecutive trials (60 s maximum for a trial; 30 s ITI
spent on platform), with each block being separated by 2 h and each
mouse being released from a different quadrant for each trial. The place
trials data were analyzed over 5 blocks of trials (4 trials/block) in which
each block represented the performance level for each of 5 consecutive
days. Escape path length, latency, and swimming speeds were analyzed as
performance variables for the cued and place trials. A probe trial was
administered1 h after completion of the place trials on the fifth day of
testing to evaluate retention of the platform location. During the 60 s
probe trial, the escape platform was removed and a mouse was placed in
the quadrant diagonally opposite from the previous platform location.
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Times spent in the pool quadrants and the number of crossings made
over the platform location (platform crossings) were recorded. Repeated-
measures ANOVA (rmANOVA) models containing one between-subjects
variable (treatment) and one within-subjects (repeated measures) variable
(e.g., blocks of trials)were typically used to analyze the learning andmemory
data. The Huynh–Feldt adjustment of  levels was used for all within-
subjects effects containing more than two levels to protect against viola-
tions of sphericity/compound symmetry assumptions underlying
rmANOVA models. Pairwise comparisons were conducted after rele-
vant, significant overall rmANOVAeffects, whichwere subjected to Bon-
ferroni’s correction when appropriate.
fcOIS. Following a previously published fcOIS protocol (White et al.,
2011), mice were anesthetized with ketamine-xylazine (108 mg/kg ket-
amine, 17mg/kg xylazine) and were placed on a rectally monitored heat-
ing pad maintained at 37°C (mTCII; Cell Microcontrols) with the head
secured in a stereotactic frame. A midline incision was made, the scalp
reflected, and the intact skull was kept moist with mineral oil. Sequential
illumination was provided at four wavelengths by a ring of light-emitting
diodes (LEDs) placed10 cmabove the head (for details, seeWhite et al.,
2011). Diffuse reflected light was detected by a cooled, frame-transfer
EMCCD camera (iXon 897; Andor Technologies). The LED ring and
camera were computer controlled and operated at a full frame rate of 30
Hz. The field of view covered themajority of the convexity of the cerebral
cortex (1 cm2). Data from all mice were subjected to an initial quality
check before spectroscopic analysis. Data runs (5min) inwhich temporal
variation in reflected light level intensity exceeded 1% for anywavelength
were excluded from further analysis. This preliminary analysis resulted in
15–45 min of data per mouse. For each pixel, the differential light inten-
sity at each wavelength was converted to differential absorption. The
multiwavelength absorption coefficient data were then converted to he-
moglobin concentration changes for each pixel and time point. The sub-
sequent fc analysis used the spatiotemporal HbO2 data (White et al.,
2009). Data were filtered to the functional connectivity band (0.009–
0.08 Hz) following previous human fMRI algorithms (Fox et al., 2005),
resampled from 30 to 1 Hz, and a brain mask was created containing all
pixels labeled as brain. Time traces of all brain pixels were averaged to
create a global brain signal. This global signal was regressed from each
pixel’s time trace to remove global sources of variance, as is common in
human fMRI algorithms. All image sequences and brain masks were
affine transformed to a common atlas space (Franklin andPaxinos, 1996)
determined by the coordinates of olfactory bulb and cerebrum, bregma,
and lambda. The anterior–posterior stretch was set equal to the medial–
lateral stretch. To ensure that all comparisons were performed only on
the brain area visualized in all mice, the intersection of each brain mask
was calculated and made symmetric. Seed placement was determined a
priori using an anatomical atlas (Franklin and Paxinos, 1996). Four seed
locations were positioned at coordinates corresponding to left and right
motor, somatosensory, retrosplenial, and visual cortices. Seed time traces
were calculated by averaging time traces within 0.25 mm (30 pixels) of a
seed locus and functional connectivity maps were created by correlating
each seed time trace against those in every brain pixel. Individual func-
tional connectivity maps were averaged within each cohort to generate
consensus maps for each cohort. Regional bilateral correlations were
determined by correlating the seed-based time trace in each functional
area with that of its contralateral homolog, thus producing six bilateral
correlation values for each mouse. Pearson r values were converted to
Fisher Z measures using: Z(r)  arctanh (r) for all group comparisons.
To further examine bilateral connectivity across the brain, every pixel in
the brain was used as a seed center and its time trace was correlated with
its contralateral homolog. Individual bilateral maps were averaged
within each cohort to generate consensus bilateral connectivitymaps. To
calculate the number (degree) of functional connections of a given pixel
(node), the full pixel-to-pixel correlation matrix was computed for each
mouse over the entire brain. Any node having a correlation coefficient,
z(r), that was0.25 was considered a connection and given a value of
1; those with a correlation coefficient 0.25 were given a value of 0.
Summing over the rows of this binarized matrix produces an un-
weighted measure of node degree for all candidate regions. Statistical
significance was determined by one-tailed t test if two groups were
compared. When variance differed significantly between groups,
Welch’s t test was used. One-way ANOVA followed by Tukey’s post
hoc test for multiple comparisons were used when more than two
groups were compared.
Cranial window implantation, topical application of antibodies, and
multiphoton imaging. APP/PS1 mice were anesthetized with isoflurane
(1.5%) and a 4mmpiece of skull was drilled to expose the cortical surface
as described previously (Spires et al., 2005). After removing the dura, 50
l of each antibody stock (1.0 mg/ml) was topically applied before ce-
menting the cranial window with a 5 mm glass coverslip. For a subset of
experiments, both anti-HA and anti-apoE HJ6.3 antibodies were labeled
with DyLight594 fluorophore following the manufacturer’s instructions
(Thermo Scientific). Awax ringwas built along the border of thewindow
to create a wall of water for the objective during imaging. Each mouse
received an intraperitoneal injection of methoxy-XO4 (5 mg/kg) 24 h
before surgery, a fluorescent compound that crosses the blood–brain
barrier (BBB) and binds to plaques (Bacskai et al., 2002). Texas red or
fluorescein dextran (70,000 Da molecular weight; 12.5 mg/ml in sterile
PBS; Invitrogen) was also injected into a lateral tail vein to provide a
fluorescent angiogram so that the shape of the vasculature would be used
as a landmark to follow the exact same fields of view over time.Mice were
imaged right after surgery and 14 d thereafter. The density of plaque in
each field of view was quantified using ImageJ by reporting the total
number of amyloid deposits per volume of cortex imaged. Each cortical
volume was defined starting from surface of the brain to the last slice in
which an amyloid deposit could be detected. In vivo imaging data sum-
marizing the amount of “stable,” “absent,” and “new” plaques were or-
ganized in a contingency table and analyzed using a  2 test. The size of
amyloid deposits was evaluated by measuring their cross-sectional area
from the maximal intensity after 2D projection. We calculated the ratio
between the size of each plaque just after surgery (t  0) and 2 weeks
(t 14 d) after topical application of each antibody. After the in vivo
imaging on t  14 d, the mice were killed for postmortem analysis of
pathology. Data in all figures are expressed as mean  SEM unless
otherwise specified.
Multiphoton imaging. In vivo multiphoton imaging was performed
using an Olympus FluoView FV1000MPE multiphoton laser-scanning
Figure 1. Reduction of A plaque deposition by the anti-apoE antibody HJ6.3. Seven-
month-old female APP/PS1 mice received 10 mg/kg weekly intraperitoneal injections of HJ6.3
or PBS for 21 weeks. A, Brain sections of the HJ6.3- or PBS-treated mice were stained with the
anti-A antibody HJ3.4B. Scale bar, 1 mm. B, A plaque load in cortex, thalamus, and hip-
pocampus were quantified (n 13–17/group; *p 0.05).
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system mounted on an Olympus BX61WI
microscope and an Olympus 25 objective
(numerical aperture 1.05). A DeepSee Mai
Tai Ti:sapphire mode-locked laser (Mai Tai;
Spectra-Physics) generated two-photon ex-
citation at 800 nm, and detectors containing
three photomultiplier tubes (Hamamatsu)
collected emitted light in the range of 420–
460, 495–540, and 575–630 nm. Mice were
placed on the microscope stage, heated using
a heating pad, and feedback regulation was
obtained from a rectal temperature probe
(Harvard Apparatus). Z-series (2 m steps,
depth of 200 m, 512  512 pixels) were
taken to cover a large surface of the window.
The laser power was measured and adjusted
before each imaging and the settings of the
photomultiplier tubes were maintained un-
changed throughout the different imaging
sessions.
Postmortem analysis after in vivo imaging.
Serial paraffin sections at 4 m thickness or
frozen sections at 40mthickness were immu-
nostained with rabbit anti-human amyloid
(N) antibody (Immuno-Biological Laborato-
ries) andThioS. Immunostained brain sections
were scanned using a Nanozoomer slide scan-
ner (Hamamatsu Photonics). For the postmor-
tem analysis after in vivo imaging, images were
taken (1.25, 20) using an Olympus BX51
epifluorescence upright microscope equipped
with a CCD camera model DP70 (Olympus).
For the localization analysis of HJ6.3 (see Fig.
10), images were acquired on a Zeiss LSM 510
META confocal microscope equipped with two-photon Coherent Cha-
meleon laser. Quantitative analyses of amyloid load and plaque density
were done using the BIOQUANT software (version 6.90.10;MBSR) after
application of an optical threshold. This software is coordinated with the
motorized stage of an upright Leica DMRBmicroscope equipped with a
CCD camera (model DC330; DAGE-MTI). Immunostained amyloid
plaques were thresholded under the 10 objective after background cor-
rection to avoid uneven lighting. Results of plaque load were analyzed
using a nonparametric Mann–Whitney test because the data did not
follow a normal distribution (according to the D’Agostino and Pearson
test). For each staining method independently, a mixed-effect model
with treatment as the fixed effect andmouse and section withinmouse as
the random effects was fitted to assess the differences between treated
groups in the value of plaque size (with log of plaque size as the outcome)
while accounting for variability between mice and section within mice.
The plaque size ratios were compared between each treatment using
one-way ANOVA followed by post hoc Tukey multiple comparison tests.
Results
HJ6.3 decreased A plaque load in the brain of APP/PS1 mice
To determine whether an anti-apoE antibody decreased A de-
position in APP/PS1 mice that had already developed significant
A deposition, we assessed APP/PS1 mice after 5 months of pe-
ripheral administration of HJ6.3 (10mg/kg/week).We immuno-
stained A plaques using an A-specific antibody HJ3.4B (Fig.
1A). In cerebral cortex immediately dorsal to the hippocampus,
HJ6.3 decreased plaque load by 20% (Fig. 1B). In thalamus,
HJ6.3 decreased plaque load by a greater amount (40%; Fig.
1B). In hippocampus, HJ6.3 did not significantly change plaque
load compared with the PBS group (Fig. 1B).
To determine whether fibrillar plaques were altered by HJ6.3,
we stained brain sectionswithThioS (Fig. 2A).HJ6.3 significantly
reduced ThioS plaque load in cortex (Fig. 2B, top). In thalamus
(Fig. 2B, middle), plaque load was reduced by 40%, whereas in
hippocampus, plaque load was not changed (Fig. 2B, bottom).
Changes of brain and blood apoE levels resulting from
HJ6.3 treatment
Because apoE is the direct target of the anti-apoE antibodyHJ6.3,
we investigated whether peripheral administration of HJ6.3 al-
Figure 2. Attenuation of fibrillar amyloid deposition by the anti-apoE antibody HJ6.3. Seven-month-old female APP/PS1mice
received 10 mg/kg weekly intraperitoneal injections of HJ6.3 or PBS for 21 weeks until 12 months of age. A, Fibrillar amyloid
plaques on brain sections of the HJ6.3- or PBS-treated mice were stained with ThioS. Scale bar, 500 m. B, Quantification of
fibrillar amyloid plaque load in cortex, thalamus, and hippocampus (n 13–17/group; *p 0.05; **p 0.01).
Figure 3. Effects of the anti-apoE antibody HJ6.3 on brain apoE. Seven-month-old female
APP/PS1mice received10mg/kgweekly intraperitoneal injections ofHJ6.3 or PBS for 21weeks.
ApoE in the cortex of the HJ6.3- or PBS-treated mice was immunostained with HJ6.8B (A) and
the percentage area covered by the stainingwas quantified (B) (n 15–18/group; *p 0.05;
**p 0.01). Scale bar, 400m.
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tered apoE levels in brain and blood. Immunostaining using an
apoE antibody directed to a different apoE epitope, HJ6.8B,
showed decreased apoE immunostaining in the cerebral cortex in
HJ6.3-treated mice (Fig. 3A,B). Biochemical analysis of apoE in
the brain tissue lysates demonstrated that apoE was decreased
primarily in the 1% Triton X-100 fraction, whereas the levels in
the PBS and 5 M guanidine fraction were unaltered (Fig. 4A, top).
In plasma, there was no change in apoE levels due to HJ6.3 (Fig.
4B, top).
HJ6.3 influenced A levels in brain and blood
To determine whether the anti-apoE antibody HJ6.3 affects A
accumulation and solubility in the brain, we did a three-step
sequential extraction of cortical tissue using PBS, 1% Triton
X-100, and 5 M guanidine. Ax-40 was then analyzed in each frac-
tion (Fig. 4A). In the PBS-soluble fraction, HJ6.3 treatment had
no significant effects on Ax-40. In the Triton X-100 fraction, in
which the apoE level was significantly lower in the HJ6.3-treated
group, Ax-40 was significantly reduced by HJ6.3. In the 5 M gua-
nidine fraction, which contains the insoluble A and	100 the
A present in the other fractions, Ax-40 was reduced signifi-
cantly. The combination of all fractions of Ax-40 showed similar
findings as the guanidine fraction because this fraction contains
the majority of A in the brain of plaque-bearing mice (Fig. 4A).
In plasma, HJ6.3 treatment resulted in a 40–60% increase in
Ax-40 without affecting apoE levels (Fig. 4B).
Effects of HJ6.3 onmicroglial activation
To determine whether HJ6.3 had an impact onmicroglial activa-
tion, we immunostained brain sections of the mice treated with
HJ6.3 or PBS using CD45, a marker of activated microglia (Fig.
5A). In cerebral cortex, the CD45 staining load was decreased by
40% after HJ6.3 treatment (Fig. 5B).
Anti-apoE antibody HJ6.3 improves spatial learning but slows
motor responses
To determine whether HJ6.3 produced functional effects in APP/
PS1 mice, we assessed HJ6.3- or PBS-treated mice starting at 11
months of age on several behavioral tests 4 months after begin-
ning treatment. We first evaluated the mice on a 1 h locomotor
activity test and a battery of sensorimotor measures followed by
the MWM. The rmANOVAs conducted on the cued trials data
from the MWM showed that the HJ6.3- and PBS-treated groups
did not differ in terms of path length (Fig. 6A) or latency (data not
shown) to find the platform and escape out of the water. This
suggests that the two groups exhibited similar levels of cued
learning performance. However, the results of an rmANOVA
revealed that the HJ6.3-treated mice swam significantly more
slowly than the PBS-treated group during certain blocks within
the cued trials (treatment effect: F(1,35) 6.99, p 0.012; treat-
ment  blocks of trials interaction: F(4,140)  3.37, p  0.025).
Subsequent pairwise comparisons showed that significant differ-
Figure 4. Effects of the anti-apoE antibody HJ6.3 on A and apoE levels in the brain and blood. A, The cortices of the HJ6.3- or PBS-treated mice were homogenized in PBS, followed
by 1% Triton X-100 and 5 M guanidine (Guan). ApoE and Ax-40 levels in the brain tissue lysates in the PBS, Triton X-100, and Guan fractions were measured by ELISA. The level of apoE
and Ax-40 in all fractions combined is also shown (n 10 –18/group). B, Plasma apoE and Ax-40 levels in HJ6.3- and PBS-treated animals were measured by ELISA (n 15–18/group;
*p 0.05; **p 0.01).
Figure5. Effects of the anti-apoE antibodyHJ6.3 onmicroglial activation. Seven-month-old
femaleAPP/PS1mice received10mg/kgweekly intraperitoneal injections ofHJ6.3 or PBS for 21
weeks until 12 months of age. Activated microglia in the cortex were immunostained with
anti-CD45 antibody (A) and the area covered by CD45 stainingwas quantified (B) (n 15–18/
group; *p 0.05). Scale bar, 400m.
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ences were found for block 3 (p 0.004)
and large differences were also observed
on blocks 2 (p  0.037), 4 (p  0.014),
and 5 (p 0.015). Together, these results
suggest that nonassociative influences
(e.g., sensorimotor, visual, or motiva-
tional disturbances) did not affect the per-
formance of the HJ6.3-treated mice
relative to the PBS-treated controls in
terms of simple cued learning. Due to dif-
ferences in swimming speeds, we used
path length to evaluate acquisition perfor-
mance in the place trials of the water
maze.
In contrast to the cued trials results, an
rmANOVA of the path length data from
the place (spatial learning) trials showed
that the HJ6.3-treated mice had signifi-
cantly shorter path lengths to the sub-
merged platform across trials (Fig. 6B)
compared with the PBS-treated control
mice (treatment effect: F(1,35) 4.79, p
0.035), with differences being greatest
during block 3 (p  0.019). In addition,
similar to the results from the cued trials,
the HJ6.3-treatedmice swam significantly
more slowly than the PBS-treated controls
during certain blocks within the place tri-
als (treatment effect: F(1,35)  13.51, p 
0.0008; treatment blocks of trials inter-
action: F(4,140)  4.01, p  0.005), with
pairwise comparisons showing that sig-
nificant differences occurred during
blocks 2–5 (p  0.001). Analysis of the
probe trial data indicated that the groups
did not differ in terms of platform cross-
ings (data not shown) or time spent in the
target quadrant. The HJ6.3-treated mice
did, however, show a spatial bias for the
target quadrant (Fig. 6C) in that they spent significantly more
time in the target quadrant relative to the times they spent in each
of the other quadrants (p  0.014), whereas the PBS-treated
group did not show a spatial bias for the target quadrant. Overall,
these results suggest thatHJ6.3 improved spatial learning in APP/
PS1 mice.
HJ6.3 improves brain functional connectivity in
APP/PS1 mice
To determine whether HJ6.3 antibody treatment restored dis-
rupted functional connectivity in the mouse brain, we compared
functional connectivity patterns (Fig. 7A) in APP/PS1 mice
treated with HJ6.3 and PBS using fcOIS (White et al., 2011; Bero
et al., 2012). We have shown previously that fcOIS is a sensitive
imaging modality capable of measuring functional connectivity
between brain regions in healthymice (White et al., 2011; Bero et
al., 2012) and that there is functional disruption in APP/PS1mice
after A deposition (White et al., 2011; Bero et al., 2012). APP/
PS1 mice treated with HJ6.3 exhibited improved bilateral func-
tional correlation strength in visual cortex with trends toward
improvement in motor and somatosensory cortices (Fig. 7A,B).
To more closely assess the effects of HJ6.3 on global bilateral
functional connectivity, full-field bilateral functional connectiv-
ity maps were created for every mouse and averaged within each
cohort (Fig. 7C). Compared with PBS-treated mice, bilateral
functional connectivity in the HJ6.3 group appeared to be more
globally restored and to resemble that of healthy, wild-type mice
(Fig. 7C), as described previously (White et al., 2011; Bero et al.,
2012). Although bilateral connectivitymagnitude provides a use-
ful metric of homotopic interhemispheric connectivity, this is
only a limited measure of the rich connectivity structure other-
wise observed over themouse brain. To examinemore closely the
effects of HJ6.3 on the topology of functional connectivity, we
analyzed the number of functional connections (node degree) in
the four brain regions investigated (Fig. 7D). From this analysis,
we observed significant increases in the node degree of motor,
somatosensory, retrosplenial, and visual cortices compared with
the PBS-treated group.
Lack of potential side effects on cholesterol, CAA, and
CAA-associated microhemorrhage
Being a key apolipoprotein in certain lipoprotein complexes,
apoE plays an important role in plasma lipid metabolism. Given
that the plasma cholesterol level of apoE-deficientmice is fivefold
higher than that of wild-type mice, a potential side effect of apoE
passive immunotherapy is that the apoE antibodies could elevate
the cholesterol level by lowering plasma apoE levels or blocking
Figure 6. HJ6.3 treatment improved spatial learning performance in the MWM. Seven month-old female APP/PS1 mice re-
ceived 10mg/kg weekly intraperitoneal injections of HJ6.3 or PBS for 21 weeks until 12 months of age. During the last 4 weeks of
treatment, the performance of HJ6.3-treated (n 19) and PBS-treated (n 18)mice in theMWM taskwas tested.A, The HJ6.3-
andPBS-treatedmicedidnotdiffer inperformancewith regard topath lengthduring the cued trials.B, However, theHJ6.3-treated
mice exhibited significantly improved performance in terms of showing decreased path length during the place (spatial learning)
trials comparedwith the PBS-treated group (treatment effect: *p 0.035), with differences being greatest during block 3 (†p
0.019). C, PBS-treated mice did not show a spatial bias for the target quadrant during the probe trial because they did not spend
significantly more time in that quadrant compared with the times in each of the other quadrants. In contrast, the HJ6.3-treated
mice did show a spatial bias for the target quadrant because they spent significantly more time in the target quadrant compared
with the times spent in each of the other pool quadrants (*p 0.014).
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apoE function. We found that injection of the anti-apoE anti-
body HJ6.3 did not affect plasma cholesterol (Fig. 8A).
In previous studies of active and passive immunization in-
volving the generation of certain anti-A antibodies, an increase
of CAA and CAA-associated microhemorrhage has been ob-
served (Pfeifer et al., 2002). To determinewhether passive immu-
notherapy targeting apoE results in similar side effects, we
assessed CAA and CAA-associated microhemorrhage. The CAA
present on the cortical surface stained with A-specific antibody
HJ3.4B was quantified. HJ6.3 did not alter the relative area cov-
ered byCAA comparedwith the PBS-treated group (Fig. 8B). The
amount of CAA-associated microhemorrhage in APP/PS1 mice
at 12 months of age was low and we did not detect any increase
in CAA-associated microhemorrhage
associated with HJ6.3 administration
(Fig. 8C).
Topical application of the anti-apoE
HJ6.3 dynamically alters amyloid
deposition over 2 weeks
To further assess early dynamic changes in
amyloid deposition associated with apoE
immunotherapy, HJ6.3 or IgG subtype-
matched anti-HA (i.e., irrelevant epitope)
control antibodies were topically applied
to the surface of brain and in vivo two-
photon microscopy was used to monitor
A plaques the day of surgery (t 0) and
14 d after antibody treatment (t  14 d).
After 2 weeks of incubation, the same
fields of view were imaged again and am-
yloid plaques were classified as “absent”
when they could not be found again, “sta-
ble” when they were imaged again, and
“new” for newly formed deposits over the
2 weeks of incubation. Althoughmost de-
posits were stable over time, direct appli-
cation of HJ6.3 reduced the amount of
newly formed plaques (“new” plaques)
and was associated with clearance of some
amyloid deposits (“absent” plaques; Fig.
9A,B).
To further establish the connection be-
tween the presence of anti-apoE antibody
and changes in amyloid deposition,
fluorescent-labeled DyLight 594-HJ6.3
antibody was applied to the surface of the
brain. We confirmed that the anti-apoE
antibody HJ6.3 can bind directly to intra-
parenchymal amyloid deposits and to
CAA (Fig. 10A). Some A plaques, espe-
cially those located deeper within the cor-
tical parenchyma, were not stained with
DyLight 594-HJ6.3 antibody, likely due to
limitations in diffusion over the several
hours of observation. To determine the
type of plaques that were bound by DyLight
594-HJ6.3, brain sections were immuno-
stainedwithanti-A antibodyafter the appli-
cation of the DyLight 594-conjugated
antibody. Immunohistochemistry showed
that DyLight 594-HJ6.3 can also bind
small, methoxy-XO4-negative nonfibril-
lar plaques, as well as methoxy-XO4-positive fibrillar plaques
(Fig. 10B). Interestingly, we observed that 91% of the “absent”
plaques that could not be detected after 14 d were previously
labeled with HJ6.3 (Fig. 11A,B). At the same time, 56% of “sta-
ble” plaqueswere also boundbyHJ6.3, but the ratio of plaque size
of these deposits decreased between 0 and 14 d, a change that was
not observed with nonlabeled plaques or with the anti-HA con-
trol antibody (Fig. 11C,D). We therefore concluded that topical
application of anti-apoE antibody HJ6.3 acutely modified the
course of amyloid deposition over 2 weeks, leading to the clear-
ance of a small percentage of amyloid plaques while leading to
shrinkage of others, a process associated with a direct interaction
Figure 7. HJ6.3 treatment improved brain functional connectivity assessed by fcOIS. Seven-month-old female APP/PS1 mice
received 10mg/kgweekly intraperitoneal injections of HJ6.3 or PBS for 21weeks. At the age of 12months, fcOISwas performed to
assess the resting state functional connectivity of the brain before euthanizing themice.A, Composite, group-averaged, functional
correlationmaps of motor, somatosensory, retrosplenial, and visual cortices in HJ6.3-treated (n 15) and PBS-treated (n 14)
APP/PS1 mice. Black circles denote seed position. B, Regional bilateral functional correlation of PBS-treated (blue) and HJ6.3-
treated (red)APP/PS1mice.C, Consensusbilateral functional connectivitymapsgenerated forHJ6.3 andPBS treatedAPP/PS1mice
and age-matched untreated wild-type B6C3 mice. The maps for age-matched wild-type B6C3 mice were regenerated from the
data reported in Bero et al. (2012).D, Node degree inmotor, somatosensory, retrosplenial, and visual cortices (*p 0.05; **p
0.01).
Figure8. Noeffects ofHJ6.3onplasmacholesterol, CAA, or CAA-associatedmicrohemorrhage. Seven-month-oldAPP/PS1mice
received 10 mg/kg weekly intraperitoneal injections of HJ6.3 or PBS for 21 weeks until 12 months of age. A, Total plasma
cholesterol levels. B, CAA on the surface of the cortex was identified by anti-A antibody HJ3.4B immunostaining and the area
covered by CAA was quantified. C, CAA-associated microhemorrhage was detected by Prussian blue and ThioS costaining (n
13–18/group).
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between the anti-apoE antibody and apoE
present within A deposits.
Acute exposure with HJ6.3 also affects
nonfibrillar A plaques
As mentioned previously, acute exposure
with HJ6.3 for 2 weeks significantly al-
tered the dynamic of amyloidosis, a phe-
nomenon associated with the direct
binding of anti-apoE antibody to apoE-
bound amyloid deposits. We then aimed
at determining whether these changes
could also be observed by postmortem
immunohistological analysis. Amyloid
load and amyloid plaque density were
evaluated 15 d after topical application
with the anti-apoE HJ6.3 or anti-HA an-
tibodies (Fig. 12A). The stereological
analysis specifically focused on the amy-
loid deposits present within the cortical
area underneath the cranial window. To
correct for interindividual variability, the
results were normalized for each mouse
for the amount of plaques in the hip-
pocampus, a deeper cerebral area that was
not in contact with the antibodies. The
plaque number per square millimeter af-
ter HJ6.3 topical application was signifi-
cantly lower by 40% compared with
anti-HA control antibody (Fig. 12C);
however, the plaque load per square mil-
limeterwas not changed significantly (Fig.
12B). This was likely because the overall
effect on plaques was modest and the
plaques most affected have the smallest
cross-sectional area and thus likely have a
proportionately small impact on themea-
sure of amyloid burden. Surprisingly,
ThioS staining showed no differences in
Figure 9. In vivo imaging of A plaques after topical application of the anti-apoE antibody HJ6.3. Fifty microliters of the anti-apoE antibody HJ6.3 or anti-HA control antibody (1.0mg/ml) were
topically applied to the brain surface of 5- to 7-month-old APP/PS1 mice. Plaques were monitored through the cranial window using two-photon microscopy the day of surgery and 14 d after
treatment, following the exact same fields of view over time. A, Representative in vivo images of amyloid plaques the day of surgery (t 0) and 14 d (t 14 d) after topical application of control
(anti-HA) or the anti-apoE antibody HJ6.3. Yellow andwhite arrows respectively show “absent” and “new” plaques. Scale bar, 100m.B, Contingency table summarizing the number of “absent,”
“stable,” and “new” plaques 2 weeks after topical application of the anti-apoE antibody HJ6.3 and anti-HA antibodies (n 7/group; p 0.0001, 2 test).
Figure 10. Affinity of fluorescent-labeled DyLight 594-apoE antibody HJ6.3 to CAA and A plaques. Fifty micrograms of
fluorescently labeled DyLight 594-apoE antibody HJ6.3 or DyLight 594-anti-HA control antibody (1.0 mg/ml) were topically
applied to the brain surface of 5- to 7-month-old APP/PS1mice. Plaques and CAAwere imaged by in vivo two-photonmicroscopy
and immunohistochemistry with the rabbit anti-human A (N) antibody (Immuno-Biological Laboratories). A, Representative
photographs of in vivo imaging after 30min of incubationwith antibody, showing that only the DyLight 594-apoE antibody HJ6.3
canbindapoE inCAA (yellowarrow)andamyloidplaques (white arrow)after a single topical application to thebrain. Scale bar, 100
m. B, Representative photographs of immunohistochemistry after 2 h of incubation with antibody, showing that the DyLight
594-apoE antibody HJ6.3 can bind apoE in small, methoxy-XO4-negative amyloid plaque (yellow arrow) and in a methoxy-XO4-
positive amyloid plaque (white arrow) after a single topical application to the brain. Scale bar, 50m.
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either plaque load or plaque number per square millimeter (data
not shown) between HJ6.3 and anti-HA control antibody. In
addition, whereas the distribution of plaque size tended to show
that HJ6.3 topical application preferentially affected smaller de-
posits when assessed by immunohistological staining (p 0.075;
Fig. 12D), no such trend was observed with the ThioS staining
(data not shown). These results may indicate that, whereas small
changes were observed on dense-core plaques by in vivo two-
photon imaging, acute exposure with anti-apoE antibody pri-
marily decreased the density of less fibrillar small amyloid
deposits.
Discussion
In the present study, we report that peripheral weekly adminis-
tration of apoE antibodies into mice with preexisting A plaques
attenuates plaque load and insoluble A without causing signif-
icant side effects such as hypercholesterolemia, CAA, or CAA-
associated microhemorrhage. ApoE levels in the brain were
decreased by antibody treatment and A levels in the blood were
increased. Importantly, anti-apoE antibody treatment improved
spatial learning performance during place trials in theMWMand
enhanced the resting-state bilateral functional connectivity in
different cortical regions. In vivo two-photon microscopic imag-
ing demonstrated that HJ6.3 bound to A plaques and cleared
some of them or led to their shrinkage, particularly those con-
taining apoE. Together, the data suggest that further develop-
ment of anti-apoE antibodies may be warranted as a potential
therapeutic strategy.
One of the major mechanisms for removal of the plaques in
response to some anti-A antibodies is microglial-mediated
phagocytosis (Bard et al., 2000; Demattos et al., 2012). For apoE
passive immunotherapy, we previously observed an increase of
reactive microglia with a 14 d short-term passive immunization
with HJ6.3 (Kim et al., 2012), suggesting the involvement of mi-
croglia in the antibody-mediated A removal. In the present
study, 5 months of weekly administration of the anti-apoE anti-
body HJ6.3 decreased microglial activity. This time-dependent
change in microglial activation agrees with the pattern observed
withA passive immunization, inwhich short-termA antibody
administration with certain anti-A antibodies increases reactive
microglia whereas long-term administration decreases reactive
microglia (Wilcock et al., 2003; Wilcock et al., 2004b). The de-
crease of microglial activation associated with long-term immu-
Figure 11. In vivo dynamic measurement of A plaques after treatment with HJ6.3. Fifty microliters of fluorescently labeled DyLight 594-apoE antibody HJ6.3 or DyLight 594-anti-HA control
antibody (1.0 mg/ml) were topically applied to the brain surface of 5- to 7-month-old APP/PS1 mice. Plaques were monitored by two-photon microscopy. A, Representative in vivo images of the
fluorescently labeled DyLight 594-HJ6.3 andmethoxy-XO4 the day of application (t 0) or 14 d after (t 14 d), showing that the plaque that got cleared (yellow arrow)was previously labeled by
DyLight 594-HJ6.3, as opposed to nonlabeled plaque (white arrow). Scale bar, 100m. B, Contingency table summarizing the number of “absent,” “stable,” and “new” plaques according to their
initial bindingwith anti-apoE HJ6.3 and anti-HA antibodies. C, Representative in vivo images of the fluorescently labeled DyLight 594-HJ6.3 andmethoxy-XO4 the day of application (t 0) or 14 d
after (t 14 d), showing that the size of HJ6.3-labeled plaque decreased after topical application of labeledHJ6.3 (yellowarrow), as opposed to nonlabeled plaque (indicated bywhite arrow). Scale
bar, 100m.D, Graphbar indicating the size ratiobetweenday0andday14after topical applicationof the control antibodyor theanti-apoEantibodyHJ6.3 (n3/group; *p0.05, ***p0.001
for one-way ANOVA followed by post hoc Tukey test and p 0.0001 for 2 test).
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nization is likely a consequence of reduced plaque load and
associated microgliosis (Liu et al., 2001). Although our present
study does not rule out the possibility that anti-apoE antibody-
mediated phagocytosis plays a role in the clearance of A colo-
calized with apoE in the plaques, it may suggest that apoE
antibody could suppress A pathology through additionalmech-
anisms via modifying apoE levels or function. ApoE plays an
important role in amyloidosis progression (Dodart et al., 2005;
Hudry et al., 2013). Previous work has shown that apoE colocal-
izes with newly formed A deposits and that apoE4 carriers show
more apoE containing newly formed plaques than individuals
with other apoE genotypes, suggesting the involvement of apoE
in the initiation of plaque formation (Thal et al., 2005). In the
chronic treatment experiment of the present study, HJ6.3 was
more effective at decreasing A deposits in thalamus than in
cortex and hippocampus, likely due to the fact that thalamus has
fewer initial preexisting plaques than cortex and hippocampus.
Furthermore, the fact that chronic but not acute application of
anti-apoE antibody decreased fibrillar plaques may also suggest
that the major effect of the anti-apoE antibody was to suppress
amyloidosis progression, as opposed to removing preexisting
plaques.
The in vivo two-photon microscopy experiments provided
direct evidence that the anti-apoE antibody prevented the forma-
tion of new plaques and decreased the size of existing plaques
upon binding. This was particularly true for plaques containing
apoE. Collectively, our data suggest that the anti-apoE antibody
HJ6.3 is able to suppress further A deposition and to enhance
the clearance or shrinkage of a small percentage of plaques after
antibody application if plaques are bound by the HJ6.3 antibody.
Importantly, when peripherally administrated into mice with
preexistingAdeposition, the anti-apoE antibodyHJ6.3was able
to improve spatial learning performance and functional connec-
tivity in addition to its effects on A pathology.
The role of apoE in AD pathogenesis has been studied exten-
sively, but there is still debate regarding whether increasing or
decreasing apoE is the best strategy in regard to AD therapeutics
(Ashford, 2002; Teter et al., 2002). LXR agonists have been shown
to decrease A deposition in the brain while modestly increasing
apoE expression (Koldamova et al., 2005; Zelcer et al., 2007; Fitz
et al., 2010). However, these agents also strongly increase apoE
lipidation by increasing ABCA1 and affecting other inflamma-
tory mechanisms. Conversely, blocking the interaction between
apoE and A (Sadowski et al., 2006) and decreasing the apoE
level by overexpressing low-density lipoprotein receptor (Kim et
al., 2009) or haploinsufficiency of apoE (Bales et al., 1999; Holtz-
man et al., 2000; Kim et al., 2011; Bien-Ly et al., 2012) results in
decreased amyloidosis. The anti-apoE antibody in the present
study did not alter plasma apoE levels while decreasing apoE level
in the brain, as detected by immunostaining associated with
plaques, providing evidence that lowering A-associated apoE in
the brain plays a beneficial role in A-amyloid-related pathogen-
esis. Interestingly, using biochemical analysis after anti-apoE an-
tibody treatment, apoE levels decreased mainly in the Triton
X-100 fraction of the cortical tissue extract. It is unlikely that the
change of apoE in theTritonX-100 fraction is only a consequence
of the reduction of coaggregated A in the Triton X-100 fraction
because, if this were the case, we would have expected apoE to
decrease in the guanidine fraction where the A levels changed as
well. In fact, the apoE level in the guanidine fraction was not
changed. Triton X-100 is a nonionic detergent that is widely used
to extract molecules and lipids from lipid-containing structures
such as cell membranes. Our observation suggests the possibility
that the anti-apoE antibody HJ6.3 targeted apoE associated with
brain lipids and suppressed amyloidosis.
Interestingly, the anti-apoE antibody HJ6.3 increased plasma
A levels without affecting plasma apoE. For certain A antibod-
ies, such as m266, increases of peripheral A has been observed
because antibody prevented A from being degraded via binding
to it and potentially increasing net A efflux out of the brain
(DeMattos et al., 2002; Yamada et al., 2009). If a similar mecha-
nism occurred in the present study, then apoE antibody could
stabilize apoE as well as A associated with apoE. However, we
found that the plasma apoE level did not increase along with A
levels upon binding with antibodies. Therefore, the increase of
Figure 12. Reduction of the number of amyloid plaques after acute exposure with the anti-
apoE antibody HJ6.3. Fifty microliters of the anti-apoE antibody HJ6.3 or anti-HA control anti-
body (1.0 mg/ml) were topically applied to the brain surface of 5- to 7-month-old APP/PS1
mice. A, Fifteen days after application, amyloid plaques were stained with the rabbit anti-
humanA (N) antibody (Immuno-Biological Laboratories). Scale bars: top, 2mm; bottom, 100
m. B, C, Bar graphs summarizing the amyloid load (B) and plaque number (C) quantified in
the cortical region under the cranial window, normalized to the amount of plaques within the
hippocampus.D, Graphbar representing theplaque sizedistributionbetween theapplicationof
the control antibody and the anti-apoE antibody HJ6.3 (n 9/group; *p 0.05, nonparamet-
ric Mann–Whitney test).
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plasmaA could bemediated through anothermechanism that is
due to a central or peripheral effect. Expression of apoE3 and
apoE4 in the mouse brain results in diminished efflux of A into
the blood compared with apoE2 (Hudry et al., 2013). Overex-
pression of an apoE receptor, a low-density lipoprotein receptor,
lowers the brain apoE level and enhances the rate of brain-to-
blood transportation of A (Castellano et al., 2012). In the pres-
ent study, HJ6.3 may be enhancing A transport across the BBB
or enhancing its CSF/ISF to plasma flow via decreasing the apoE
level or sequestering apoE.
Increased CAA and CAA-associated microhemorrhage (Pfe-
ifer et al., 2002; Wilcock et al., 2004a) are side effects associated
with previous passive A immunotherapy, especially with those A
antibodies that target aggregated forms of A if the effector func-
tion of the antibody is intact (Pfeifer et al., 2002; Wilcock et al.,
2004a; Racke et al., 2005). The mechanism of the anti-A
antibody-induced increase of CAA associated microhemorrhage
is not entirely clear. The anti-apoE antibody HJ6.3 did not cause
a detectable increase of CAA or CAA-associated microhemor-
rhages. This may be due to the anti-apoE antibody enhancing
both apoE and A clearance, but via a different mechanism from
certain A antibodies that favor A clearance but may enhance
A transport along the interstitial fluid surrounding arterioles
where CAA forms. Although apoE is known to play a key role in
CAA development (Holtzman et al., 2000; Fryer et al., 2003),
therapeutic antibodies targeting apoE may induce fewer or no
side effects associated with CAA. The somewhat modest effect of
the anti-apoE antibody HJ6.3 on established CNS amyloid levels
may also contribute to the lack of CAA andCAA-associated brain
microhemorrhages. In addition, the APP/PS1 mice that we used
in these studies had a relatively small amount of CAA. In future
studies, it will be important to compare some of the differences in
anti-A-associated versus anti-apoE-associated effects of CAA
and CAA-associated brain hemorrhage in another mouse model.
In addition, it will be important to assess the effects of anti-apoE
antibodies in animals that express human apoE isoforms. Such
experiments may lead to a better understanding of the involve-
ment and consequences of both apoE and A in plaque and CAA
formation and aid in treatment development.
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